CJC-1295 (No DAC) + Ipamorelin

Overview

CJC-1295 (No DAC) and Ipamorelin are synthetic peptides commonly studied in endocrine and growth hormone research. When used together in experimental settings, they are often investigated for their complementary effects on growth hormone (GH) pulsatility and secretion dynamics.

CJC-1295 (No DAC) is a modified analog of growth hormone-releasing hormone (GHRH 1–29) designed to stimulate endogenous GH release through pituitary GHRH receptor activation, with a shorter half-life compared to its DAC-modified counterpart.

Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor (GHS-R1a) agonist. It is studied for its ability to stimulate GH release in a more selective manner, with minimal reported activity on prolactin or cortisol pathways in experimental models.

Together, these peptides are frequently examined in research exploring synergistic stimulation of pulsatile growth hormone release.

Mechanism of Action

CJC-1295 (No DAC) and Ipamorelin act on distinct but complementary pathways involved in growth hormone regulation.

CJC-1295 (No DAC)

✓ Mimics endogenous GHRH (growth hormone-releasing hormone)

✓ Binds to GHRH receptors in the anterior pituitary

✓ Stimulates pulsatile secretion of growth hormone

✓ Enhances downstream IGF-1 signaling in experimental models

✓ Shorter systemic activity compared to DAC-modified versions

Ipamorelin

✓ Selective agonist of ghrelin receptor (GHS-R1a)

✓ Stimulates growth hormone release from somatotroph cells

✓ Minimal observed activity on cortisol or prolactin in studies

✓ Supports GH pulse amplitude in research models

Combined Research Mechanism

When studied together, CJC-1295 (No DAC) and Ipamorelin are hypothesized to:

✓ Activate complementary GH secretion pathways (GHRH + ghrelin axis)

✓ Enhance pulsatile GH release patterns

✓ Increase overall GH secretion magnitude in experimental settings

✓ Improve temporal GH signaling dynamics (pulse frequency and amplitude)

Important: These mechanisms are based on preclinical and limited clinical research. Synergistic effects are still under investigation.

Research Applications

CJC-1295 (No DAC) + Ipamorelin are commonly studied in the following research domains:

Endocrine Research

• Growth hormone secretion dynamics

• Pituitary signaling pathways

• GHRH and ghrelin receptor interaction studies

• Hormonal pulsatility modeling

Metabolic Research

• IGF-1 axis regulation

• Lipid metabolism pathways

• Glucose homeostasis models

• Energy balance signaling

Musculoskeletal Research

• Muscle protein synthesis pathways (experimental models)

• Connective tissue regeneration studies

• Bone metabolism and remodeling research

Aging and Cellular Research

• Cellular regeneration pathways

• Age-related GH decline models

• Mitochondrial function studies

• Tissue repair mechanisms

Neuroendocrine Research

• Hypothalamic-pituitary axis regulation

• Neurohormonal feedback loops

• Central regulation of growth signaling

Technical Specifications

Stability & Storage

Lyophilized Form

• Store at -20°C for long-term preservation

• Keep protected from light and moisture

• Avoid repeated freeze-thaw cycles

Reconstituted Solution

• Store at 2–8°C

• Use sterile handling procedures

• Stability varies depending on solvent and conditions

Stability Notes

Both peptides are generally stable in lyophilized form under proper storage conditions. After reconstitution, degradation rates depend on temperature, solvent composition, and microbial control.

Pharmacokinetic Notes (Research Data)

CJC-1295 (No DAC)

• Extended but non-permanent GHRH receptor activity

• Shorter half-life compared to DAC-modified analogs

• Supports intermittent GH release patterns

Ipamorelin

• Short systemic half-life in experimental models

• Rapid receptor binding and signal activation

• GH release typically observed in pulsatile form

Note: Both peptides primarily influence downstream hormonal cascades rather than maintaining sustained direct activity.

Selected Research References / PubMed Keywords

Researchers may explore literature using the following keywords:

CJC-1295 (No DAC)

• CJC-1295 no DAC

• growth hormone releasing hormone analog

• GHRH receptor agonist peptide

• pulsatile growth hormone secretion

Ipamorelin

• Ipamorelin peptide

• growth hormone secretagogue receptor agonist

• ghrelin receptor GHS-R1a

• selective GH release peptide

Combined Research Topics

• GHRH and ghrelin synergy

• growth hormone pulse amplitude

• endocrine axis regulation peptides

• IGF-1 stimulation research models

Research Use Only Disclaimer

FOR RESEARCH USE ONLY

This material is intended exclusively for laboratory research by qualified professionals.

This product:

• Is not approved for human use

• Is not approved for veterinary use

• Is not intended to diagnose, treat, cure, or prevent any disease

• Is not a dietary supplement

• Must not be used in clinical or therapeutic applications

All information provided reflects published scientific literature and experimental research contexts. Results observed in vitro or in animal models may not translate to human physiology.